文献速递白血病

儿童急性淋巴细胞白血病泼尼松龙药代动力学与治疗反应关系评估

Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
PubMed 文献 · Br J Haematol · 2021-06-01

本研究基于荷兰儿童肿瘤学组方案,纳入124例新诊断儿童急性淋巴细胞白血病患者,分析1028份泼尼松龙血浆浓度,建立群体药代动力学模型并检验游离药物AUC与治疗结局的关系。结果显示游离泼尼松龙AUC与疾病参数或治疗结局无关,血浆蛋白结合随年龄下降,未观察到暴露量对临床结局的影响,不支持个体化给药。

要点

  • 游离泼尼松龙AUC与疾病参数及治疗结局均无关联。
  • 血浆蛋白结合随年龄下降,游离药物浓度与年龄相关。
  • 未观察到暴露量影响临床结局,不支持个体化给药。

核心结论

  • 游离泼尼松龙AUC与任何疾病参数或治疗结局均无关联。
  • 未观察到暴露量对临床治疗结局参数的影响,不支持个体化给药。

研究设计与样本

  • 基于荷兰儿童肿瘤学组研究,纳入124例0-18岁新诊断ALL患儿,共1028份结合与游离泼尼松龙血浆浓度。
  • 建立群体药代动力学模型,并将事后AUC与治疗结局参数进行检验。

主要发现

  • 游离泼尼松龙药代动力学最佳描述为异速增长缩放及与蛋白的可饱和结合。
  • 血浆蛋白结合随年龄下降。
  • 游离泼尼松龙AUC与任何疾病参数或治疗结局均无关联。
  • 游离泼尼松龙血浆浓度与年龄相关。
  • 不良缓解者、高危和复发患者相比良好缓解者显示暴露量较低的趋势,但不良缓解者组样本量小,需进一步研究。

临床怎么用

  • 基于现有数据,不支持根据游离泼尼松龙暴露量进行个体化给药。

局限性

  • 不良缓解者组样本量小,相关趋势需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucocorticoids form the backbone of paediatric acute lymphoblastic leukaemia (ALL) treatment. Many studies have been performed on steroid resistance; however, few studies have addressed the relationship between dose, concentration and clinical response. The aim of the present study was to evaluate the pharmacokinetics of prednisolone in the treatment of paediatric ALL and the correlation with clinical parameters. A total of 1028 bound and unbound prednisolone plasma concentrations were available from 124 children (aged 0-18 years) with newly diagnosed ALL enrolled in the Dutch Childhood Oncology Group studies. A population pharmacokinetic model was developed and post hoc area under the curve (AUC) was tested against treatment outcome parameters. The pharmacokinetics of unbound prednisolone in plasma was best described with allometric scaling and saturable binding to proteins. Plasma protein binding decreased with age. The AUC of unbound prednisolone was not associated with any of the disease parameters or treatment outcomes. Unbound prednisolone plasma concentrations correlated with age. No effect of exposure on clinical treatment outcome parameters was observed and does not substantiate individualised dosing. Poor responders, high-risk and relapsed patients showed a trend towards lower exposure compared to good responders. However, the group of poor responders was small and requires further research.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sassen SDT, Mathôt RAA, Pieters R, et al. Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. Br J Haematol. 2021. PMID: 34060065. doi:10.1111/bjh.17572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。